ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.06/06/2010 בקשה לשינוי משטר מינון the recommended dose is 500 mg at intervals of one month, with an additional 500 mg dose given two weeks after the initial dose.

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - bicalutamide - טבליה - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0) casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - zolmitriptan - טבליות מתמוססות בפה - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - budesonide 0.5 mg / 2 ml - suspension for inhalation - budesonide - bronchial asthma, especially in cases where other therapy is insufficient or unsuitable.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - budesonide 1 mg / 2 ml - suspension for inhalation - budesonide - bronchial asthma, especially in cases where other therapy is insufficient or unsuitable.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - budesonide micronized 4 mg/ml - suspension for inhalation - budesonide - bronchial asthma.

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib

ישראל - עברית - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 3 years and over as a booster following primary immunisation . adacel polio is not indicatd for primary immunisation. adacel polio is not indicated for treating diseases caused by b. pertussis, c.diphtheriae or c. tetani or by poliomyelitis infections.

ישראל - עברית - Ministry of Health

sanofi israel ltd - poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated - תרחיף להזרקה - poliovirus type 1 inactivated 40 u/vial; poliovirus type 2 inactivated 8 u/vial; poliovirus type 3 inactivated 32 u/vial - poliomyelitis vaccines - prophylaxis of poliomyelitis.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b.